Search

Your search keyword '"P. Pautier"' showing total 83 results
Start Over Author "P. Pautier" Search Limiters Peer Reviewed
83 results on '"P. Pautier"'

1. Immune checkpoints are predominantly co-expressed by clonally expanded CD4+FoxP3+ intratumoral T-cells in primary human cancers

Author

Bredel, Delphine, Tihic, Edi, Mouraud, Séverine, Danlos, François-Xavier, Susini, Sandrine, Aglave, Marine, Alfaro, Alexia, Mohamed-Djalim, Chifaou, Rouanne, Mathieu, Halse, Héloise, Bigorgne, Amélie, Tselikas, Lambros, Dalle, Stéphane, Hartl, Dana M., Baudin, Eric, Guettier, Catherine, Vibert, Eric, Rosmorduc, Olivier, Robert, Caroline, Ferlicot, Sophie, Parier, Bastien, Albiges, Laurence, de Montpreville, Vincent Thomas, Besse, Benjamin, Mercier, Olaf, Even, Caroline, Breuskin, Ingrid, Classe, Marion, Radulescu, Camélia, Lebret, Thierry, Pautier, Patricia, Gouy, Sébastien, Scoazec, Jean-Yves, Zitvogel, Laurence, Marabelle, Aurélien, and Bonvalet, Mélodie

Published
2023
Full Text
View/download PDF

3. Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial

Author

Mir, Olivier, Ferrua, Marie, Fourcade, Aude, Mathivon, Delphine, Duflot-Boukobza, Adeline, Dumont, Sarah, Baudin, Eric, Delaloge, Suzette, Malka, David, Albiges, Laurence, Pautier, Patricia, Robert, Caroline, Planchard, David, de Botton, Stéphane, Scotté, Florian, Lemare, François, Abbas, May, Guillet, Marilène, Puglisi, Vanessa, Di Palma, Mario, and Minvielle, Etienne

Published
2022
Full Text
View/download PDF

11. “Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors”

Author

Gernier, François, Ahmed-Lecheheb, Djihane, Pautier, Patricia, Floquet, Anne, Nadeau, Cédric, Frank, Sophie, Alexandre, Jérôme, Selle, Frédéric, Berton-Rigaud, Dominique, Kalbacher, Elsa, Orfeuvre, Hubert, Lortholary, Alain, Augereau, Paule, Labombarda, Fabien, Perrier, Lionel, Grellard, Jean-Michel, Licaj, Idlir, Clarisse, Bénédicte, Savoye, Aude-Marie, Bourien, Héloise, De La Motte Rouge, Thibaut, Kurtz, Jean-Emmanuel, Kerdja, Katia, Lelaidier, Anaïs, Charreton, Amandine, Ray-Coquard, Isabelle, and Joly, Florence

Published
2021
Full Text
View/download PDF

12. Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.

Author

Marmé, Frederik, Harter, Philipp, Redondo, Andres, Reuss, Alexander, Ray-Coquard, Isabelle Laure, Lindemann, Kristina, Kurzeder, Christian, Van Nieuwenhuysen, Els, Bellier, Charlotte, Pietzner, Klaus, El-Balat, Ahmed, García-Duran, Carmen, Wimberger, Pauline, Perez-Fidalgo, Jose Alejandro, Selle, Frederic, de Gregorio, Nikolaus, Burges, Alexander, Romero, Ignacio, Hasenburg, Annette, and Pautier, Patricia

Published
2024
Full Text
View/download PDF

15. Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative

Author

Auguste, Aurélie, Genestie, Catherine, De Bruyn, Marco, Adam, Julien, Le Formal, Audrey, Drusch, Françoise, Pautier, Patricia, Crosbie, Emma J., MacKay, Helen, Kitchener, Henry C., Powell, Melanie, Pollock, Pamela M., Mileshkin, Linda, Edmondson, Richard J., Nout, Remi, Nijman, Hans W., Creutzberg, Carien L., Bosse, Tjalling, and Leary, Alexandra

Published
2018
Full Text
View/download PDF

16. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.

Author

Kurtz, Jean-Emmanuel, Pujade-Lauraine, Eric, Oaknin, Ana, Belin, Lisa, Leitner, Katharina, Cibula, David, Denys, Hannelore, Rosengarten, Ora, Rodrigues, Manuel, de Gregorio, Nikolaus, Martinez García, Jeronimo, Petru, Edgar, Kocián, Roman, Vergote, Ignace, Pautier, Patricia, Schmalfeldt, Barbara, Gaba, Lydia, Polterauer, Stephan, Mouret Reynier, Marie-Ange, and Sehouli, Jalid

Published
2023
Full Text
View/download PDF

17. European multidisciplinary tumor boards support cross-border networking and increase treatment options for patients with rare gynecological tumors.

Author

Joneborg, Ulrika, Bergamini, Alice, Wallin, Emelie, Mangili, Giorgia, Solheim, Olesya, Marquina, Gloria, Casado, Antonio, Rokkones, Erik, Coulter, John, Lok, Christianne A. R., van Trommel, Nienke, Amant, Frédéric, Bolze, Pierre-Adrien, Sehouli, Jalid, Han, Sileny, Kridelka, Frédéric, Goffin, Frederic, Pautier, Patricia, Ray-Coquard, Isabelle, and Seckl, Michael

Published
2023
Full Text
View/download PDF

18. Impact of primary para-aortic lymphadenectomy on distant failure in locally advanced cervical cancer patients treated in the era of image-guided adaptive brachytherapy

Author

Chargari, Cyrus, Mazeron, Renaud, Dunant, Ariane, Gouy, Sébastien, Petit, Claire, Maroun, Pierre, Uzan, Catherine, Annede, Pierre, Bentivegna, Enrica, Balleyguier, Corinne, Genestie, Catherine, Pautier, Patricia, Leary, Alexandra, Lhomme, Catherine, Deutsch, Eric, Morice, Philippe, and Haie-Meder, Christine

Published
2016
Full Text
View/download PDF

20. Breast Cancer Patients' Experience and Wishes Regarding Communication on Sexual Health: The BEROSE Study

Author

M. Aupomerol, D. Chaltiel, P. Pautier, D. Wehrer, L. Véron, L. Degousée, L. Fasse, L. Guéroult-Accolas, A. Di Meglio, F. Scotté, A. De-Jesus, I. Vaz-Luis, S. Delaloge, M. Lambertini, and B. Pistilli

Subjects
Cancer Research, Oncology, Communication, Surveys and Questionnaires, Humans, Breast Neoplasms, Female, General Medicine, Sexual Health, Medical Oncology
Abstract

BEROSE is a single-center observational study, which aimed to determine the proportion of women with breast cancer who received information on sexual health from health professionals throughout their whole care pathway. A total of 318 women with all stages of breast cancer (30% metastatic) and at different time interval from diagnosis (up to 7 years) participated to the survey. Sixty-five percent of women reported that they had not received any information about sexual health over the whole care. Increased awareness among the healthcare professionals and particularly the oncology community is needed to discuss sexual health in women with breast cancer.

Published
2022

22. 535P Long term quality of life after chemotherapy among nonepithelial ovarian cancer survivors: The case-control vivrovaire rare tumours study

Author

F. Joly Lobbedez, I.L. Ray-Coquard, S. Lefevre Arbogast, J-M. Grellard, B. Clarisse, A. Floquet, F. Selle, D. Berton-Rigaud, S. Frank, T. De La Motte Rouge, E. Kalbacher, M. Provansal Gross, null A. lortholary, H. Orfeuvre, J. Alexandre, P. Augereau, J.E. Kurtz, C. Nadeau, P. Pautier, and F. Gernier

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

23. Efficacy of chemotherapy according to BRCA status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse.

Author

Brouillard-Saby, Flora, Saint-Martin, Caroline, Ray-Coquard, Isabelle, Gladieff, Laurence, Pomel, Christophe, Colombo, Pierre-Emmanuel, Classe, Jean-Marc, Chevrier, Marion, Joly, Florence, De la Motte Rouge, Thibault, Floquet, Anne, Sabatier, Renaud, Barranger, Emmanuel, Costaz, Hélène, Leblanc, Eric, Marcha, Frédéric, Pautier, Patricia, Bosquet, Lise, and Rodrigues, Manuel

Published
2023
Full Text
View/download PDF

25. 596P CA125 longitudinal decline kinetic is complementary to BRCA testing in first-line high grade serous ovarian carcinoma (HGSOC) patients (pts)

Author

O. Becker, M. Chevrier, L. Gladieff, F. Joly Lobbedez, I.L. Ray-Coquard, A. Floquet, C. Pomel, H. Costaz, P. Pautier, T. De La Motte Rouge, R. Sabatier, J-M. Classe, E. Leblanc, F. Marchal, P-E. Colombo, E. Barranger, O. Colomban, L. Bosquet, B. You, and M.J. Rodrigues

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

28. LBA30 Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)

Author

J.E. Kurtz, E. Pujade-Lauraine, A. Oaknin, L. Belin, I. Tsibulak, D. Cibula, I.B. Vergote, O.S. Rosengarten, M.J. Rodrigues, N. de Gregorio, J. Martinez-Garcia, P. Pautier, M.A. Mouret Reynier, F. Selle, V. D'Hondt, F. Joly Lobbedez, E. Bultot Boissier, A. Floquet, P-E. Heudel, and F. Heitz

Subjects
Oncology, Hematology
Published
2022
Full Text
View/download PDF

29. Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.

Author

Pfisterer, Jacobus, Joly, Florence, Kristensen, Gunnar, Rau, Joern, Mahner, Sven, Pautier, Patricia, El-Balat, Ahmed, Kurtz, Jean-Emmanuel, Canzler, Ulrich, Sehouli, Jalid, Heubner, Martin L., Hartkopf, Andreas D., Baumann, Klaus, Hasenburg, Annette, Hanker, Lars C., Belau, Antje, Schmalfeldt, Barbara, Denschlag, Dominik, Park-Simon, Tjoung-Won, and Selle, Frédéric

Published
2023
Full Text
View/download PDF

46. Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer --a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34).

Author

Harter, Philipp, Pautier, Patricia, Van Nieuwenhuysen, Els, Reuss, Alexander, Redondo, Andres, Lindemann, Kristina, Kurzeder, Christian, Petru, Edgar, Heitz, Florian, Sehouli, Jalid, Degregorio, Nikolaus, Wimberger, Pauline, Burges, Alexander, Cron, Nadin, Ledermann, Jonathan, Lorusso, Domenica, Paoletti, Xavier, and Marme, Frederik

Subjects
BEVACIZUMAB, CANCER chemotherapy, OVARIAN cancer, HEALTH outcome assessment, IMMUNOTHERAPY
Abstract

Background Improvement in clinical outcomes of patients with platinum-resistant disease is an unmet medical need and trials in this population are urgently needed. Checkpoint-inhibitors have already shown activity in multiple other tumor entities and ovarian cancer, especially in the combination with anti-angiogenic treatment. Primary objective To test if the activity of nonplatinum-based chemotherapy and bevacizumab could be improved by the addition of atezolizumab. study hypothesis The addition of atezolizumab to standard non-platinum combination of chemotherapy and bevacizumab improves median overall survival from 15 to 20 months. Trial design Patients are randomized to chemotherapy (paclitaxel weekly or pegylated liposomal doxorubicin) + bevacizumab + placebo vs chemotherapy + bevacizumab + atezolizumab. Stratification factors are: number of prior lines, planned type of chemotherapy, prior use of bevacizumab, and tumor programmed death-ligand 1 (PDL1) status. Major inclusion/exclusion criteria Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer with up to three prior therapies and a treatmentfree interval after platinum of less than 6 months. Patients with three prior lines of chemotherapy are eligible irrespective of the platinum free-interval. A de novo tumor tissue sample biopsy for determination of PD-L1 status prior to randomization for stratification is mandatory. Major exclusion criteria consider bevacizumab-specific and immunotherapy-specific criteria. Primary endpoint Overall survival and progression-free survival are co-primary endpoints. sample size It is planned to randomize 664 patients. Trial registration NCT03353831. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

47. Localized high grade endometrial stromal sarcoma and localized undifferentiated uterine sarcoma: a retrospective series of the French Sarcoma Group.

Author

Meurer, Marie, Floquet, A, Ray-Coquard, I, Bertucci, F, Auriche, M, Cordoba, A, Piperno-Neumann, S, Salas, S, Delannes, M, Chevalier, T, Italiano, A, J, Y Blay, Mancini, Julien, Pautier, P, and Duffaud, F

Subjects
ENDOMETRIAL surgery, ADJUVANT treatment of cancer, SARCOMA, GYNECOLOGY, CANCER chemotherapy
Abstract

Objective: High grade endometrial stromal sarcoma and undifferentiated uterine sarcomas are associated with a very poor prognosis. Although large surgical resection is the standard of care, the optimal adjuvant strategy remains unclear. Methods: A retrospective analysis of patients with localized high grade endometrial stromal sarcoma and undifferentiated uterine sarcomas (stages I–III) treated in 10 French Sarcoma Group centers was conducted. Results: 39 patients with localized high grade endometrial stromal sarcoma and undifferentiated uterine sarcomas treated from 2008 to 2016 were included. 24/39 patients (61.5%) were stage I at diagnosis. 38/39 patients underwent surgical resection, with total hysterectomy and bilateral oophorectomy completed in 26/38 (68%). Surgeries were mostly resection complete (R0, 23/38, 60%) and microscopically incomplete resection (R1, 6/38, 16%). 22 patients (58%) underwent postoperative radiotherapy (including brachytherapy in 11 cases), and 11 (29%) underwent adjuvant chemotherapy. After a median follow-up of 33 months (range 2.6–112), 17/39 patients were alive and 21/39 (54%) had relapsed (9 local relapses and 16 metastases). The 3 year and 5 year overall survival rates were 49.8% and 31.1%, respectively, and 3 year and 5 year disease free survival rates were 42.7% and 16.0%, respectively. Median overall survival and disease free survival were 32.7 (95% CI 16.3–49.1) and 23 (4.4–41.6) months, respectively. Medians were, respectively, 46.7 months and 39.0 months among those who underwent adjuvant radiotherapy and 41.0 months and 10.3 months for those who underwent adjuvant chemotherapy. In multivariate analysis, adjuvant radiotherapy was an independent prognostic factor for overall survival (P=0.012) and disease free survival (P=0.036). Chemotherapy, International Federation of Gynecology and Obstetrics I–II stages, and Eastern Cooperative Oncology Group-performance status 0 correlated with improved overall survival (P=0.034, P=0.002, P=0.006), and absence of vascular invasion (P=0.014) was associated with better disease free survival. Conclusions: The standard treatment of primary localized high grade endometrial stromal sarcoma and undifferentiated uterine sarcomas is total hysterectomy and bilateral oophorectomy. The current study shows that adjuvant radiotherapy and adjuvant chemotherapy appear to improve overall survival. A prospective large study is warranted to validate this therapeutic management. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

48. Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting.

Author

Ray-Coquard, I., Trama, AnnaLisa, Seckl, M.J., Fotopoulou, C., Pautier, P., Pignata, S., Kristensen, G., Mangili, G., Falconer, H., Massuger, L., Sehouli, J., Pujade-Lauraine, E., Lorusso, D., Amant, F., Rokkones, E., Vergote, I., and Ledermann, J.A.

Subjects
GYNECOLOGIC cancer, TUMORS, EPIDEMIOLOGY
Abstract

Abstract Purpose of the review More than 50% of all gynaecological cancers can be classified as rare tumours (defined as an annual incidence of <6 per 100,000) and such tumours represent an important challenge for clinicians. Recent findings Rare cancers account for more than one fifth of all new cancer diagnoses, more than any of the single common cancers alone. Reviewing the RARECAREnet database, some of the tumours occur infrequently, whilst others because of their natural history have a high prevalence, and therefore appear to be more common, although their incidence is also rare. Harmonization of medical practice, guidelines and novel trials are needed to identify rare tumours and facilitate the development of new treatments. Ovarian tumours are the focus of this review, but we comment on other rare gynaecological tumours, as the diagnosis and treatment challenges faced are similar. Future This requires European collaboration, international partnerships, harmonization of treatment and collaboration to overcome the regulatory barriers to conduct international trials. Whilst randomized trials can be done in many tumour types, there are some for which conducting even single arm studies may be challenging. For these tumours alternative study designs, robust collection of data through national registries and audits could lead to improvements in the treatment of rare tumours. In addition, concentring the care of patients with rare tumours into a limited number of centres will help to build expertise, facilitate trials and improve outcomes. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

49. Multimodal Management of Locally Advanced Neuroendocrine Cervical Carcinoma: A Single Institution Experience.

Author

Castelnau-Marchand, Pauline, Pautier, Patricia, Genestie, Catherine, Leary, Alexandra, Bentivegna, Enrica, Gouy, Sébastien, Scoazec, Jean-Yves, Morice, Philippe, Haie-Meder, Christine, and Chargari, Cyrus

Abstract

Objective: The aim of this study was to report our institutional experience of a multimodal approach for treatment of locally advanced high-grade neuroendocrine cervical cancer. Methods and Materials: Patients with primary locally advanced neuroendocrine cervical cancer diagnosed between 2001 and 2014 were included. The scheduled treatment sequence was as follows: pelvic +/− para-aortic radiotherapy (according to tumor stage), associated with chemotherapy based on platine-derivate and etoposide regimen, followed with a brachytherapy boost, then completion surgery if there was no progression +/− consolidation etoposide chemotherapy (for a total of 5–6 cycles). Disease-free survival (DFS) and overall survival (OS) were reported and prognostic factors were searched. Results: A total of 24 patients fulfilled inclusion criteria. Median age was 48 (range 22–77 years). Fourteen patients (58%) had pelvic lymph node metastases. After chemoradiation/brachytherapy, a radical hysterectomy could be performed in 18 of 24 patients (75%). Histologically complete resection was achieved in 14 (78%) of 18 patients. Complete pathological response was reported in 7 (39%) of 18. With median follow-up of 29.7 months, 10 (42%) of 24 patients experienced tumor relapse, all associated with distant failure, including one local failure. The DFS and OS rates estimated at 3 years were 55% and 63%, respectively. Lymph node metastases and tumor stage were prognostic for DFS (P = 0.016 and P = 0.022, respectively). Complete resection was associated with a lower incidence of relapses, as compared with microscopically incomplete resection (P = 0.04). A total of 12 (86%) of 14 patients with histologically complete resection were in complete remission at last follow-up. Apart from manageable acute hematological toxicities, most treatment complications were mild to moderate. Conclusions: This series based on a multimodal management compares favorably with previously published data. Most patients could be eligible to surgery, and complete remission was achieved in 85% of those amenable to complete resection. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

50. Characteristics and Prognosis of Stage I Ovarian Mucinous Tumors According to Expansile or Infiltrative Type.

Author

Gouy, Sebastien, Saidani, Marine, Maulard, Amandine, Bach-Hamba, Slim, Bentivegna, Enrica, Leary, Alexandra, Pautier, Patricia, Devouassoux-Shisheboran, Mojgan, Genestie, Catherine, and Morice, Philippe

Abstract

Background: The present study retrospectively determined the outcomes and prognoses in stage Imucinous ovarian carcinoma according to histological type (ie, expansile or infiltrative). Methods: A centralized pathologic review of tumors in patients treated from 1976 to 2016 for ovarian mucinous carcinoma was performed by 2 expert pathologists according to the 2014 World Health Organization classification. Only patients with stage I disease were analyzed. Tumors were typed as expansile or infiltrative and oncological issues analyzed. Results: A total of 114 cases were reviewed. Fifty were excluded (stage 9 I in 30 cases and no accessibility to a pathological review for 20 cases). Thus, 64 patients fulfilled the inclusion criteria: 29 had expansile-type and 35 infiltrative-type disease. The characteristics of both groups of patients were comparable, except the use of nodal staging surgery, which was more frequent in patients with infiltrative type. The International Federation of Gynecology and Obstetrics stages in expansile and infiltrative types were as follows: IA in 13 (45%) and 20 (57%), and IC in 16 (55%) and 15 (43%), respectively. Recurrence occurred in 3 patients with expansile type and 6 patientswith infiltrative type. Two cases of expansile recurrence had pelvic recurrence and were salvaged after secondary surgery and chemotherapy, whereas 5 cases of infiltrative recurrence had extrapelvic spread and died from disease or were alive with progressive disease. Conclusions: Recurrence occurred in both types of stage I mucinous ovarian cancer. However, lethal recurrences were observed mainly in infiltrative type. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results